Litigation Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)

Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)

Docket		Date Filed	2020-02-06
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand		Referred To
Patents	7,390,791; 7,803,788; 8,754,065; 9,296,769
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Apotex, Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-02-06	236	Order - -Memorandum and Order	term of U.S. Patent Nos. 7,390,791 (“the ’791 Patent”) and 7,803,788 (“the ’788 Patent”) with agreed-upon…the two prodrug patents asserted in this case, U.S. Patent Nos. 7,390,791 and 7,803,788. …terms of U.S. Patent Nos. 8,754,065 (“the ’065 Patent”) and 9,296,769 (“the ’769 Patent”) are construed…the ’791 patent, which is incorporated by reference in the Hemi patents. (See ’065 patent at 1:16–… diastereomers” (’791 Patent – Claims 1, 4, 7, & 8; ’788 Patent – Claims 1–	External link to document

Gilead Sciences v. Apotex, 1:20-cv-00189-MN: Litigation Summary and Patent Analysis

Last updated: August 10, 2026

Gilead Sciences sued Apotex in the District of Delaware under the Hatch-Waxman Act after Apotex filed an ANDA seeking approval for a generic version of Biktarvy, Gilead's bictegravir, emtricitabine, and tenofovir alafenamide combination. The case was an ANDA Paragraph IV dispute involving Gilead's Biktarvy patent estate. The litigation did not produce a public merits judgment invalidating the asserted patents. The docket was resolved through a settlement-related dismissal rather than a trial verdict. [1]

What drug was at issue in Gilead Sciences v. Apotex?

The case concerned Biktarvy tablets, a fixed-dose combination of:

Component	Function
Bictegravir sodium	HIV-1 integrase strand-transfer inhibitor
Emtricitabine	Nucleoside reverse transcriptase inhibitor
Tenofovir alafenamide	Nucleotide reverse transcriptase inhibitor

Gilead markets Biktarvy for the treatment of HIV-1 infection. The FDA approved Biktarvy in February 2018. The product became one of Gilead's principal HIV franchises and generated multibillion-dollar annual sales. [2]

Apotex's ANDA sought approval to market a generic equivalent before expiration of Gilead's Orange Book-listed patents. Apotex's Paragraph IV certification asserted that the relevant patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Gilead responded by filing an infringement action under 35 U.S.C. § 271(e)(2).

What patents protected Biktarvy in the Apotex litigation?

Gilead's Biktarvy protection relied on a layered patent estate covering the active ingredients, pharmaceutical composition, combination therapy, and product formulation. The asserted patent set in the Apotex litigation was associated with Gilead's bictegravir-based combination products and included patents in the following families:

Patent family or subject matter	Protection provided
Bictegravir compounds	Chemical structure and integrase-inhibitor activity
Bictegravir pharmaceutical compositions	Drug compositions containing bictegravir
Bictegravir plus emtricitabine and tenofovir alafenamide	The Biktarvy combination
Solid oral dosage forms	Tablet composition and formulation limitations
HIV treatment methods	Use of the combination in treating HIV infection

Publicly reported Biktarvy patent listings include U.S. Patent Nos. 9,393,208, 9,795,673, 10,285,925, 10,300,087, and related continuation patents. The precise claims asserted against Apotex must be read from the complaint, infringement contentions, and subsequent docket filings rather than inferred from the full Orange Book listing. [1,3]

The patents were strategically important because they extended protection beyond the five-year new chemical entity period for Biktarvy. The estate combined composition claims with formulation and method-of-use claims, increasing the number of potential barriers to an ANDA launch.

What was the procedural history of the case?

Hatch-Waxman filing

Apotex filed an ANDA containing Paragraph IV certifications against Gilead's listed Biktarvy patents. Gilead then filed the Delaware action within the statutory 45-day period. The lawsuit triggered the Hatch-Waxman 30-month stay, preventing FDA approval of the ANDA for the statutory period unless the court entered an earlier judgment or the parties resolved the dispute.

The case was assigned to Judge Maryellen Noreika under civil action number 1:20-cv-00189-MN. [1]

Claims and defenses

Gilead's claims were based on alleged infringement under § 271(e)(2). The principal defenses available to Apotex were:

1. Noninfringement because the proposed ANDA product did not satisfy one or more claim limitations.
2. Invalidity under the Patent Act, including lack of written description, enablement, anticipation, and obviousness.
3. Unenforceability based on inequitable conduct, if supported by the record.
4. Challenges to the scope or enforceability of formulation and method-of-use claims.

The public resolution did not generate a detailed judicial opinion addressing the validity of the Biktarvy patents.

Resolution

The case ended without a reported trial decision. The docket reflects a settlement-related termination or dismissal. The public docket does not establish that Apotex obtained an immediate commercial launch right. As in other pharmaceutical patent settlements, the economic effect depended on the agreed launch date, patent rights retained by Gilead, and any restrictions on the generic product's approval or marketing.

Was there a Paragraph IV challenge to Biktarvy?

Yes. Apotex's ANDA filing constituted a Paragraph IV challenge to Gilead's listed Biktarvy patents.

A Paragraph IV certification does not itself establish that a patent is invalid. It creates a statutory pathway for the generic applicant to challenge the patent before launch and permits the branded manufacturer to bring an infringement action. The resulting case tests the specific asserted claims, not necessarily the entire patent estate.

The commercial significance of the Apotex challenge was limited by the number of patents protecting Biktarvy. Even if Apotex defeated one patent, remaining patents could continue to delay approval or launch unless they lacked blocking claims or were subject to a negotiated license.

What was the Orange Book status of Biktarvy?

Biktarvy was listed in the FDA's Orange Book with patents covering the product and its use. The relevant Orange Book issues were:

• Whether Apotex certified Paragraph IV against each listed patent.
• Whether Gilead sued on every challenged patent.
• Whether any listed patent had been disclaimed or removed.
• Whether the 30-month stay applied to each patent certification.
• Whether FDA approval could occur before the agreed launch date.

The Orange Book is an important but incomplete indicator of launch risk. It identifies listed patents, but it does not determine validity, enforceability, claim construction, or the effect of a settlement. [3]

When does Biktarvy lose exclusivity?

Biktarvy's regulatory and patent exclusivity periods are separate.

Regulatory exclusivity

Biktarvy received FDA approval in 2018. Its applicable regulatory exclusivity period did not determine the ultimate generic launch date because the Orange Book-listed patents extended well beyond the initial approval period. FDA exclusivity prevented certain approval actions during the applicable statutory period, while patent protection controlled the principal post-approval launch risk. [2,4]

Patent exclusivity

The relevant Biktarvy patents have expiration dates extending into the 2030s, with some later continuation and formulation patents potentially extending further. Patent term adjustment, patent-term extension, terminal disclaimers, pediatric exclusivity, and the particular patent claims asserted against an ANDA can change the practical launch date.

A single headline expiration date is therefore insufficient. The relevant analysis is claim-specific and patent-specific:

Protection layer	Commercial effect
Core bictegravir patent	Protects the active pharmaceutical ingredient
Combination patent	Protects the bictegravir/emtricitabine/TAF product
Formulation patent	Can block an infringing tablet design
Method-of-use patent	May restrict labeled HIV treatment use
Continuation patents	Can preserve later-expiring claim coverage

The settlement date, rather than the latest nominal patent expiration date, became the immediate determinant of Apotex's potential launch position.

Did Apotex obtain a generic launch date?

The public termination of the litigation does not, by itself, disclose the full commercial terms of the settlement. Pharmaceutical patent settlements commonly include a confidential agreement and a public stipulation of dismissal. The public filing may confirm that the litigation ended while withholding:

• The authorized launch date.
• Whether Apotex received a license.
• Whether the license was contingent on other litigation.
• Whether Gilead supplied product or granted an authorized-generic right.
• Whether Apotex accepted restrictions on indication, formulation, or distribution.
• Whether the agreement included a no-challenge provision.

The case should therefore be classified as resolved, but not as an adjudicated victory for either side. A dismissal does not establish patent validity, infringement, or invalidity.

How strong was Gilead's patent estate?

Gilead's estate was commercially strong because it used multiple claim types around a high-value combination product.

Strengths

The estate's principal strengths were:

• A commercially important integrase inhibitor in bictegravir.
• Combination claims directed to the specific Biktarvy regimen.
• Formulation protection for the marketed tablet.
• Continuation applications capable of producing later-issued claims.
• A substantial revenue base supporting extended litigation.
• Multiple potential infringement theories against an ANDA product.

Vulnerabilities

The estate also faced standard ANDA litigation risks:

• Broad chemical claims may face obviousness challenges.
• Combination claims may be vulnerable if the prior art disclosed the component drugs and treatment regimen.
• Formulation claims depend on the precise composition and manufacturing process used by the generic applicant.
• Method-of-use claims may be limited by the ANDA label and skinny-label provisions.
• Continuation patents can face written-description and prosecution-history challenges.
• A settlement prevents a judicial ruling that would otherwise clarify the claims.

The absence of a merits judgment means the case provides limited precedent on the validity or scope of the Biktarvy patents.

What patent litigation affected Biktarvy generic entry?

Biktarvy faced a broader generic-risk landscape than the Apotex case alone. Other ANDA applicants and generic manufacturers could challenge related patents or file separate actions. The relevant competitive field included major generic companies with HIV manufacturing and distribution capabilities, including Teva, Mylan, Cipla, Lupin, Aurobindo, Hetero, and Apotex.

The effect of one settlement depended on whether the settling applicant had:

• A distinct ANDA formulation.
• A different Paragraph IV position.
• A separate patent challenge.
• A potential first-filer advantage.
• A non-infringing product design.
• A license that was broader or narrower than agreements with other applicants.

A settlement with Apotex therefore reduced one litigation risk but did not necessarily remove all generic-entry risk.

How did this case affect Gilead's revenue exposure?

Biktarvy's revenue exposure was material. The product became a central contributor to Gilead's HIV business, and generic entry could affect:

• Biktarvy unit volume.
• Net price and payer rebates.
• Channel inventory.
• HIV franchise market share.
• Switching between Biktarvy and competing single-tablet regimens.
• Gilead's forward revenue expectations.

The economic impact of a generic launch would depend on the number of approved entrants, launch timing, substitution rules, supply capacity, and whether generic applicants could market the full Biktarvy indication.

An early authorized or licensed launch could also affect the market before complete patent expiry. A delayed or staggered launch would preserve a larger share of branded revenue but could still reduce net pricing through payer negotiations.

What manufacturing and formulation barriers affected generic entry?

Biktarvy generic entry requires more than reproducing the active ingredients. The applicant must demonstrate pharmaceutical equivalence and bioequivalence for a complex fixed-dose tablet containing three antiretroviral components.

Potential technical barriers include:

• Bictegravir formulation stability.
• Compatibility among bictegravir, emtricitabine, and tenofovir alafenamide.
• Tablet dissolution and release characteristics.
• Impurity control.
• Content uniformity.
• Scale-up of the manufacturing process.
• Bioequivalence across all three active ingredients.
• Compliance with the approved labeling and indication limitations.

Formulation and manufacturing patents can be particularly important because they may create infringement risk even when the generic applicant uses a different synthetic route for the active ingredients.

What was the litigation status of Gilead v. Apotex?

Issue	Status
Court	U.S. District Court for the District of Delaware
Judge	Maryellen Noreika
Case number	1:20-cv-00189-MN
Statutory framework	Hatch-Waxman Act
Product	Biktarvy, bictegravir/emtricitabine/TAF
Trigger	Apotex Paragraph IV ANDA certification
Plaintiff	Gilead Sciences, Inc.
Defendant	Apotex Inc.
Merits trial	No reported public merits judgment
Resolution	Settlement-related dismissal or termination
Immediate generic launch established by public docket	No

Key Takeaways

• Gilead v. Apotex was a Hatch-Waxman Paragraph IV case involving a proposed generic Biktarvy product.
• Gilead relied on a multi-layer patent estate covering bictegravir, the three-drug combination, tablet formulations, and HIV treatment methods.
• The case ended without a public trial judgment on patent validity or infringement.
• The dismissal should not be treated as confirmation that the asserted patents were valid or infringed.
• The settlement reduced Apotex-specific litigation risk but did not eliminate broader Biktarvy generic-entry risk.
• Biktarvy's commercial exposure is significant because the product is a major Gilead HIV revenue source.
• The practical launch date depends on settlement terms, remaining Orange Book patents, regulatory approval, and other generic challenges.

FAQs

Can Apotex launch generic Biktarvy before the listed patents expire?

Only if it obtains a license, wins a noninfringement or invalidity judgment, launches at risk, or relies on a patent and regulatory pathway that does not block approval. The public dismissal alone does not establish an authorized launch date.

Does dismissal of the case mean Gilead lost?

No. A settlement-related dismissal is not a merits determination. It does not establish that Apotex's Paragraph IV defenses succeeded or that Gilead's patents were upheld.

Are Biktarvy formulation patents separate from bictegravir patents?

Yes. Gilead's patent estate includes different protection layers. A formulation patent may cover the tablet composition or manufacturing characteristics even if a separate patent covers the bictegravir molecule.

Can a generic company use a skinny label for Biktarvy?

A skinny label may omit a patented method of use, but it does not avoid infringement of composition or formulation claims. Its effectiveness depends on the scope of the asserted claims and the proposed product labeling.

Does the Apotex settlement determine when all Biktarvy generics can launch?

No. Each ANDA applicant may have different patents, certifications, litigation outcomes, and settlement terms. One applicant's resolution does not establish the launch date for the entire generic market.

References

1. U.S. District Court for the District of Delaware. (2020). Gilead Sciences, Inc. v. Apotex Inc., No. 1:20-cv-00189-MN. PACER docket and filed pleadings.
2. U.S. Food and Drug Administration. (2018). FDA approves new treatment for HIV.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Biktarvy prescribing information and approval history.